BCL2L14 was upregulated by nanoparticulate tetraiodothyroacetic acid (tetrac), which reduced viable cell numbers more efficiently than unmodified tetrac in estrogen receptor-negative human breast cancer cells [78, 79]. Here, BCL2L14 is linked to breast carcinoma.